Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects

Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects

Daniel A Duprez,1 Yehuda Handelsman,2 Michael Koren3 1Cardiovascular Division, School of Medicine, University of Minnesota, Minneapolis, MN, USA; 2Metabolic Institute of America, Tarzana, CA, USA; 3Jacksonville Center for Clinical Research, Jacksonville, FL, USACorrespondence: Daniel A DuprezCardiov...

Full description

Bibliographic Details
Main Authors: Duprez DA, Handelsman Y, Koren M
Format: Article
Language:English
Published: Dove Medical Press 2020-10-01
Series:Vascular Health and Risk Management
Subjects:
atherosclerotic cardiovascular disease
hypercholesterolemia
secondary prevention
low-density lipoprotein cholesterol
major adverse cardiovascular events
Online Access:https://www.dovepress.com/cardiovascular-outcomes-and-proprotein-convertase-subtilisinkexin-type-peer-reviewed-article-VHRM

Internet

https://www.dovepress.com/cardiovascular-outcomes-and-proprotein-convertase-subtilisinkexin-type-peer-reviewed-article-VHRM

Similar Items